Premium
Expression and Signal Transduction of T‐Cell Antigen Receptor (TCR)/CD3 Complexes on Fresh or In Vitro Expanded T Lymphocytes from Patients with Hodgkin's and Non‐Hodgkin's Lymphomas
Author(s) -
RUBIN B.,
MARTIN E. P. G.,
ARNAUD J.,
DELSOL G,
PLESNER T.,
RATSIMBAZAFY A.,
LLOBERA R.,
HOLM B.,
MARIAME B.
Publication year - 1997
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1046/j.1365-3083.1997.d01-452.x
Subject(s) - cd3 , t cell receptor , lymphoma , antigen , t cell , immunology , biology , cell , cancer research , t lymphocyte , in vitro , medicine , immune system , cd8 , biochemistry
T‐cell responses against soluble antigens, alloantigens and mitogens are frequently diminished in patients with certain types of cancer. In the present study, the authors investigated possible mechanisms for the partial T‐cell immunodeficiency in patients with Hodgkin's or non‐Hodgkin's lymphomas. It was found that T‐cells from lymphoma patients had significantly reduced proliferative responses to EBV‐transformed B‐cell lines and to anti‐TCR/CD3 MoAb; a 30–50% reduction of cells expressing membrane T‐cell receptor (TCR) complexes; and a significantly reduced signal transduction function. Long‐term in vitro culture conditions were developed to expand T cells in TCR/CD3‐dependent or TCR/CD3‐independent manners. With such methods, it was found that the decreased T‐cell responses in patients with Hodgkin's and non‐Hodgkin's lymphomas appeared to be an intrinsic T‐cell defect (not at the antigen presenting cell level), and the T‐cell responses could be recovered after only a few days in culture. Thus, it is suggested that the T‐cell response–defect in Hodgkin or non‐Hodgkin lymphoma patients is a reversible phenomenon, dependent on the patient's tumour‐bearing environment.